Xenon Pharmaceuticals Inc (NASDAQ:XENE) Expected to Announce Earnings of -$0.49 Per Share
Wall Street brokerages predict that Xenon Pharmaceuticals Inc (NASDAQ:XENE) will post earnings per share (EPS) of ($0.49) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Xenon Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.61) and the highest estimate coming in at ($0.41). Xenon Pharmaceuticals reported earnings per share of ($0.33) in the same quarter last year, which suggests a negative year over year growth rate of 48.5%. The company is expected to issue its next quarterly earnings results on Tuesday, November 5th.
On average, analysts expect that Xenon Pharmaceuticals will report full year earnings of ($1.88) per share for the current year, with EPS estimates ranging from ($2.18) to ($1.68). For the next financial year, analysts anticipate that the firm will post earnings of ($1.92) per share, with EPS estimates ranging from ($2.39) to ($1.58). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Xenon Pharmaceuticals.
Xenon Pharmaceuticals (NASDAQ:XENE) last announced its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.46) by $0.09.
Shares of XENE stock traded up $0.02 during trading hours on Friday, hitting $9.34. The company had a trading volume of 914 shares, compared to its average volume of 44,583. The company’s fifty day moving average is $9.27 and its 200 day moving average is $9.49. The company has a debt-to-equity ratio of 0.18, a current ratio of 11.07 and a quick ratio of 11.07. Xenon Pharmaceuticals has a fifty-two week low of $5.41 and a fifty-two week high of $15.00. The stock has a market capitalization of $245.12 million, a PE ratio of -6.98 and a beta of 1.33.
Institutional investors and hedge funds have recently modified their holdings of the company. Sphera Funds Management LTD. boosted its position in Xenon Pharmaceuticals by 18.7% in the 1st quarter. Sphera Funds Management LTD. now owns 533,655 shares of the biopharmaceutical company’s stock valued at $5,422,000 after buying an additional 84,171 shares during the period. Northern Trust Corp grew its stake in Xenon Pharmaceuticals by 18.9% during the 4th quarter. Northern Trust Corp now owns 12,246 shares of the biopharmaceutical company’s stock worth $77,000 after purchasing an additional 1,948 shares in the last quarter. NEA Management Company LLC acquired a new position in Xenon Pharmaceuticals during the 2nd quarter worth $1,802,000. Altshuler Shaham Ltd increased its holdings in Xenon Pharmaceuticals by 4.3% during the 2nd quarter. Altshuler Shaham Ltd now owns 149,758 shares of the biopharmaceutical company’s stock worth $1,477,000 after purchasing an additional 6,151 shares during the period. Finally, Athanor Capital LP purchased a new stake in Xenon Pharmaceuticals during the 2nd quarter worth about $100,000. 68.26% of the stock is currently owned by institutional investors and hedge funds.
About Xenon Pharmaceuticals
Xenon Pharmaceuticals, Inc engages in discovering and developing therapeutics to improve the lives of patients with neurological disorders. It focuses on the treatment of epilepsy. Its products include XEN496, XEN1101, XEN901, and XEN007. The company was founded by Simon Neil Pimstone, Johannes J. P.
Read More: Current Ratio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.